<![CDATA[Breast Cancer Update]]>c9acc7bc-4c44-5c2f-a772-58cc1982de21Thu, 16 Apr 2026 20:05:11 +0000Captivate.fmDr. Neil Lovehttps://artwork.captivate.fm/ad97e2be-455a-4b53-ab3d-383838c145e5/cbjJP3tyd5NWFP4W5DD1CnhC.pngBreast Cancer UpdateDr. Neil LoveDr. Neil LoveFeaturing one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.https://www.researchtopractice.com/browse-by-tumor-types/breast-cancerfalseepisodichttps://feeds.captivate.fm/breast-oncology/nopodcastHR-Positive Metastatic Breast Cancer — An Interview with Dr Seth Wander on Optimizing Biomarker Assessment and Related Treatment Decision-MakingHR-Positive Metastatic Breast Cancer — An Interview with Dr Seth Wander on Optimizing Biomarker Assessment and Related Treatment Decision-MakingDr Seth Wander from Massachusetts General Hospital in Boston discusses the role of biomarker assessment in the management of HR-positive metastatic breast cancer.

CME information and select publications here.

]]>Dr Seth Wander from Massachusetts General Hospital in Boston discusses the role of biomarker assessment in the management of HR-positive metastatic breast cancer.

CME information and select publications here.

]]>00411b17-4521-42de-95c3-277a4bc2b944Thu, 16 Apr 2026 09:00:00 -040001:00:13falsefull25585825ER-Positive, HER2-Positive Metastatic Breast Cancer — What Clinicians Want to Know About First-Line and Maintenance TherapyER-Positive, HER2-Positive Metastatic Breast Cancer — What Clinicians Want to Know About First-Line and Maintenance TherapyDr Virginia F Borges from the University of Colorado Anschutz Medical Campus in Aurora and Dr Ian E Krop from Yale Cancer Center in New Haven, Connecticut, review clinical research data and best practices guiding the selection of first-line and maintenance therapy for patients with ER-positive, HER2-positive metastatic breast cancer.

CME information and select publications here.

]]>Dr Virginia F Borges from the University of Colorado Anschutz Medical Campus in Aurora and Dr Ian E Krop from Yale Cancer Center in New Haven, Connecticut, review clinical research data and best practices guiding the selection of first-line and maintenance therapy for patients with ER-positive, HER2-positive metastatic breast cancer.

CME information and select publications here.

]]>33cd0fc5-0e6b-4490-abd3-2a17c92dfb98Tue, 14 Apr 2026 09:00:00 -040057:59falsefull25575725Desmoid Tumors — Microlearning Activity 2 with Dr Ravin RatanDesmoid Tumors — Microlearning Activity 2 with Dr Ravin RatanDr Ravin Ratan from The University of Texas MD Anderson Cancer Center in Houston discusses available clinical data with treatment approaches for desmoid tumors, alongside clinical cases illustrating real-world application.

CME information and select publications here.

]]>Dr Ravin Ratan from The University of Texas MD Anderson Cancer Center in Houston discusses available clinical data with treatment approaches for desmoid tumors, alongside clinical cases illustrating real-world application.

CME information and select publications here.

]]>db00c7cd-61f5-44c7-9d9a-0e382b15678aTue, 07 Apr 2026 16:00:00 -040028:14falsefull25565625Diabetology in Breast Cancer — Managing Hyperglycemia in Patients with Breast Cancer Receiving Agents Targeting the PI3K/AKT/PTEN PathwayDiabetology in Breast Cancer — Managing Hyperglycemia in Patients with Breast Cancer Receiving Agents Targeting the PI3K/AKT/PTEN PathwayMs Jaime Carroll from Mayo Clinic in Rochester, Minnesota, Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, Dr Marie E McDonnell from Brigham and Women’s Hospital in Boston, Massachusetts, and Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss the incidence, prevention and management of hyperglycemia in breast cancer patients receiving PI3K/AKT/PTEN inhibitors.

CME information and select publications here.

]]>Ms Jaime Carroll from Mayo Clinic in Rochester, Minnesota, Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, Dr Marie E McDonnell from Brigham and Women’s Hospital in Boston, Massachusetts, and Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss the incidence, prevention and management of hyperglycemia in breast cancer patients receiving PI3K/AKT/PTEN inhibitors.

CME information and select publications here.

]]>286d1f98-dae2-4e31-bd0a-66b3fc7918e8Mon, 30 Mar 2026 11:00:00 -040001:15:32falsefull25555525Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Lajos Pusztai: Current and Future Role of Tumor-Informed Circulating Tumor DNA AssaysBreast Cancer — 5-Minute Journal Club Issue 2 with Dr Lajos Pusztai: Current and Future Role of Tumor-Informed Circulating Tumor DNA AssaysDr Lajos Pusztai from Yale Cancer Center in New Haven, Connecticut, discusses recent developments with circulating tumor DNA assays in the management of breast cancer.

CME information and select publications here.

]]>Dr Lajos Pusztai from Yale Cancer Center in New Haven, Connecticut, discusses recent developments with circulating tumor DNA assays in the management of breast cancer.

CME information and select publications here.

]]>d3aa5671-b388-4c23-a6a3-819eeee09294Wed, 18 Mar 2026 12:00:00 -040030:21falsefull25545425Desmoid Tumors — Microlearning Activity 1 with Dr Ravin RatanDesmoid Tumors — Microlearning Activity 1 with Dr Ravin RatanDr Ravin Ratan from The University of Texas MD Anderson Cancer Center in Houston discusses available clinical data with treatment approaches for desmoid tumors, alongside clinical cases illustrating real-world application.

CME information and select publications here.

]]>Dr Ravin Ratan from The University of Texas MD Anderson Cancer Center in Houston discusses available clinical data with treatment approaches for desmoid tumors, alongside clinical cases illustrating real-world application.

CME information and select publications here.

]]>6ae84578-245a-498b-bad7-f5b9a281842eMon, 16 Mar 2026 14:30:00 -040016:43falsefull25535325Antibody-Drug Conjugates for Breast Cancer — Year in Review Series on Relevant New Datasets and AdvancesAntibody-Drug Conjugates for Breast Cancer — Year in Review Series on Relevant New Datasets and AdvancesDr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Sara M Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data with antibody-drug conjugates in the management of breast cancer.

CME information and select publications here.

]]>Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Sara M Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data with antibody-drug conjugates in the management of breast cancer.

CME information and select publications here.

]]>1eb04f67-4d50-4b82-a5db-05b28e72309dMon, 02 Mar 2026 09:00:00 -040058:40falsefull25525225Endocrine-Based Therapy for HR-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium SeriesEndocrine-Based Therapy for HR-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium SeriesDr Angela DeMichele from the Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Seth Wander from Massachusetts General Hospital in Boston discuss real-world cases and recent clinical data surrounding the management of HR-positive breast cancer.

CME information and select publications here.

]]>Dr Angela DeMichele from the Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Seth Wander from Massachusetts General Hospital in Boston discuss real-world cases and recent clinical data surrounding the management of HR-positive breast cancer.

CME information and select publications here.

]]>3631beab-6266-4957-a81b-589c4c095f6dTue, 27 Jan 2026 14:42:00 -040002:01:07falsefull25515125HER2-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium SeriesHER2-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium SeriesProf Giuseppe Curigliano from the University of Milan in Italy, Prof Nadia Harbeck from LMU University Hospital in Munich, Germany, Dr Ian E Krop from Yale Cancer Center, Dr Nancy U Lin from Dana-Farber Cancer Institute and Dr Joyce O’Shaughnessy from Baylor University Medical Center discuss real-world cases and recent clinical data pertinent to the management of HER2-positive breast cancer.

CME information and select publications here.

]]>Prof Giuseppe Curigliano from the University of Milan in Italy, Prof Nadia Harbeck from LMU University Hospital in Munich, Germany, Dr Ian E Krop from Yale Cancer Center, Dr Nancy U Lin from Dana-Farber Cancer Institute and Dr Joyce O’Shaughnessy from Baylor University Medical Center discuss real-world cases and recent clinical data pertinent to the management of HER2-positive breast cancer.

CME information and select publications here.

]]>ee737d96-df10-4104-97ed-265e0213c607Wed, 14 Jan 2026 15:54:00 -040001:58:18falsefull25505025Antibody-Drug Conjugates for Breast Cancer — Proceedings from a San Antonio 2025 Symposium SeriesAntibody-Drug Conjugates for Breast Cancer — Proceedings from a San Antonio 2025 Symposium SeriesDr Javier Cortés from the International Breast Cancer Center in Barcelona, Spain, Dr Rita Nanda from the University of Chicago, Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood discuss key clinical data with antibody-drug conjugates for metastatic breast cancer and their expert perspectives surrounding its clinical applications.

CME information and select publications here.

]]>Dr Javier Cortés from the International Breast Cancer Center in Barcelona, Spain, Dr Rita Nanda from the University of Chicago, Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood discuss key clinical data with antibody-drug conjugates for metastatic breast cancer and their expert perspectives surrounding its clinical applications.

CME information and select publications here.

]]>4dc4914d-2220-476c-9822-a0faa60ccff6Thu, 08 Jan 2026 15:30:00 -040001:30:21falsefull25494925Toxicities Associated with Antibody-Drug Conjugates for Metastatic Breast Cancer — Clinical Investigator Perspectives on Actual Patient CasesToxicities Associated with Antibody-Drug Conjugates for Metastatic Breast Cancer — Clinical Investigator Perspectives on Actual Patient CasesDr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from The University of Chicago in Illinois engage in an evidence-based discussion around real-world cases involving common toxicities associated with antibody-drug conjugates in the management of breast cancer.

CME information and select publications here.

]]>Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from The University of Chicago in Illinois engage in an evidence-based discussion around real-world cases involving common toxicities associated with antibody-drug conjugates in the management of breast cancer.

CME information and select publications here.

]]>1dedf0e1-03e7-4a1a-83cf-eeeaba6f60fdTue, 23 Dec 2025 14:15:00 -040001:00:14falsefull25484825Breast Cancer — Highlights from the 2025 ESMO Annual MeetingBreast Cancer — Highlights from the 2025 ESMO Annual MeetingProf Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss the implications of clinical findings in breast cancer recently presented at the 2025 ESMO Annual Meeting. 

CME information and select publications here.

]]>Prof Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss the implications of clinical findings in breast cancer recently presented at the 2025 ESMO Annual Meeting. 

CME information and select publications here.

]]>feb3d440-2887-481c-a707-70745655c726Mon, 08 Dec 2025 16:15:00 -040001:27:39falsefull25474725Breast Cancer — Microlearning Activity Issue 3 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting UpdatesBreast Cancer — Microlearning Activity Issue 3 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting UpdatesDr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. 

CME information and select publications here.

]]>Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. 

CME information and select publications here.

]]>2d23f566-6a39-4ea3-85ca-7ab78cb1529aFri, 05 Dec 2025 15:00:00 -040015:27falsefull25464625Breast Cancer — Microlearning Activity 2 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting UpdatesBreast Cancer — Microlearning Activity 2 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting UpdatesDr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. 

CME information and select publications here.

]]>Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. 

CME information and select publications here.

]]>300ac0d1-f867-4a64-abd5-9a479ec7fb40Tue, 02 Dec 2025 15:10:00 -040016:55falsefull25454525Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2Dr Rinath M Jeselsohn and Dr Joyce O’Shaughnessy review current literature and datasets exploring the use of oral selective estrogen receptor degraders for the management of metastatic breast cancer. 

CME information and select publications here.

]]>Dr Rinath M Jeselsohn and Dr Joyce O’Shaughnessy review current literature and datasets exploring the use of oral selective estrogen receptor degraders for the management of metastatic breast cancer. 

CME information and select publications here.

]]>3a35e67a-a029-4b7d-b0b0-1ef4380ae9c3Sat, 29 Nov 2025 09:00:00 -040058:54falsefull25444425Breast Cancer — Microlearning Activity 1 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting UpdatesBreast Cancer — Microlearning Activity 1 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting UpdatesDr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. 

CME information and select publications here.

]]>Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. 

CME information and select publications here.

]]>584b9f75-8f92-453c-9be1-e599e2b3ec96Wed, 26 Nov 2025 10:00:00 -040012:49falsefull25434325HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor DegradersHR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor DegradersDr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, reviews available clinical data with PROTAC estrogen receptor degraders and their potential role in the management of HR-positive metastatic breast cancer. 

CME information and select publications here.

]]>Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, reviews available clinical data with PROTAC estrogen receptor degraders and their potential role in the management of HR-positive metastatic breast cancer. 

CME information and select publications here.

]]>df424f80-9dc1-4792-82bb-e3c06c4c3bf9Thu, 20 Nov 2025 15:59:00 -040058:36falsefull25424225ER-Positive Metastatic Breast Cancer — A Roundtable Discussion on the Current and Future Role of Oral SERDsER-Positive Metastatic Breast Cancer — A Roundtable Discussion on the Current and Future Role of Oral SERDsProf Francois-Clement Bidard from the Institut Curie in Paris, France, Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, Dr Rebecca Shatsky from the University of California San Diego Moores Cancer Center and Dr Seth Wander from Massachusetts General Hospital in Boston discuss recent updates on available and emerging treatment strategies involving oral SERDs for ER-positive metastatic breast cancer.  

CME information and select publications here.

]]>Prof Francois-Clement Bidard from the Institut Curie in Paris, France, Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, Dr Rebecca Shatsky from the University of California San Diego Moores Cancer Center and Dr Seth Wander from Massachusetts General Hospital in Boston discuss recent updates on available and emerging treatment strategies involving oral SERDs for ER-positive metastatic breast cancer.  

CME information and select publications here.

]]>22856258-2e23-4b78-b6cd-db077d3420c9Fri, 14 Nov 2025 15:40:00 -040002:30:36falsefull25414125Breast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research InstituteBreast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research InstituteDr Harold J Burstein, Dr Matthew P Goetz, Dr Heather McArthur and Dr Rita Nanda share their perspectives on the evolving therapeutic landscape for patients with breast cancer. 

CME information and select publications here.

]]>Dr Harold J Burstein, Dr Matthew P Goetz, Dr Heather McArthur and Dr Rita Nanda share their perspectives on the evolving therapeutic landscape for patients with breast cancer. 

CME information and select publications here.

]]>1245f76d-b305-45e6-85b0-31c4610a6dceMon, 10 Nov 2025 16:00:00 -040001:57:51falsefull25404025ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor DegradersER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor DegradersProf Patrick Neven from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies with oral SERDs for ER-positive metastatic breast cancer.   

CME information and select publications here.

]]>Prof Patrick Neven from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies with oral SERDs for ER-positive metastatic breast cancer.   

CME information and select publications here.

]]>a38f642a-3990-487a-8c3e-798262a7ac3eWed, 05 Nov 2025 15:19:00 -040041:17falsefull25393925Breast Cancer — 5-Minute Journal Club Issue 4 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesBreast Cancer — 5-Minute Journal Club Issue 4 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesKevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer. 

CME information and select publications here.

]]>Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer. 

CME information and select publications here.

]]>1c2d9dc0-6300-4289-8ca7-590f3815d993Mon, 27 Oct 2025 14:43:00 -040015:40falsefull25383825Metastatic Breast Cancer — Current and Future Integration of Antibody-Drug ConjugatesMetastatic Breast Cancer — Current and Future Integration of Antibody-Drug ConjugatesDr Aditya Bardia and Dr Adam M Brufsky discuss published and emerging datasets investigating the incorporation of antibody-drug conjugates into the treatment of metastatic breast cancer.

CME information and select publications here.

]]>Dr Aditya Bardia and Dr Adam M Brufsky discuss published and emerging datasets investigating the incorporation of antibody-drug conjugates into the treatment of metastatic breast cancer.

CME information and select publications here.

]]>3f4e612e-357a-4e85-ae6b-4e944084dbd5Tue, 21 Oct 2025 15:00:00 -040056:46falsefull25373725HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into TreatmentHR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into TreatmentDr Laura Huppert from the University of California, San Francisco, discusses approved and investigational antibody-drug conjugates in the current and future management of HR-positive and triple-negative metastatic breast cancer. 

CME information and select publications here.

]]>Dr Laura Huppert from the University of California, San Francisco, discusses approved and investigational antibody-drug conjugates in the current and future management of HR-positive and triple-negative metastatic breast cancer. 

CME information and select publications here.

]]>e702bf42-9f43-466d-901d-a61e98fcb613Tue, 14 Oct 2025 15:00:00 -040043:40falsefull25363625Breast Cancer — An ASCO 2025 ReviewBreast Cancer — An ASCO 2025 ReviewDr Sara A Hurvitz and Dr Sara M Tolaney summarize the treatment landscape for breast cancer and discuss the implications of clinical findings recently presented at the 2025 ASCO Annual Meeting. 

CME information and select publications here.

]]>Dr Sara A Hurvitz and Dr Sara M Tolaney summarize the treatment landscape for breast cancer and discuss the implications of clinical findings recently presented at the 2025 ASCO Annual Meeting. 

CME information and select publications here.

]]>d55948d6-de16-4741-ae28-e17525ba76a4Tue, 07 Oct 2025 14:00:00 -040001:02:01falsefull25353525Breast Cancer — 5-Minute Journal Club Issue 3 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesBreast Cancer — 5-Minute Journal Club Issue 3 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesDr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer. 

CME information and select publications here.

]]>Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer. 

CME information and select publications here.

]]>39747b04-75a7-4005-a2db-2cb8c6a12b16Mon, 29 Sep 2025 13:30:00 -040021:51falsefull25343425Metastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal ManagementMetastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal ManagementProf Peter Schmid from Barts Cancer Institute in London reviews available efficacy and safety data guiding the optimal management of metastatic triple-negative breast cancer. 

CME information and select publications here.

]]>Prof Peter Schmid from Barts Cancer Institute in London reviews available efficacy and safety data guiding the optimal management of metastatic triple-negative breast cancer. 

CME information and select publications here.

]]>38080bab-9070-41ec-a80e-1ebc414d96e4Tue, 23 Sep 2025 08:30:00 -040040:53falsefull25333325Metastatic Triple-Negative Breast Cancer — The Selection and Sequencing of TherapyMetastatic Triple-Negative Breast Cancer — The Selection and Sequencing of TherapyDr Ana C Garrido-Castro and Prof Peter Schmid review patient cases and provide insights regarding the treatment of metastatic triple-negative breast cancer.  

CME information and select publications here.

]]>Dr Ana C Garrido-Castro and Prof Peter Schmid review patient cases and provide insights regarding the treatment of metastatic triple-negative breast cancer.  

CME information and select publications here.

]]>5618f2c2-ea59-4027-898c-70ab1f5f1a60Thu, 18 Sep 2025 09:00:00 -040058:41falsefull25323225Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event ManagementOcular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event ManagementDr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management.   

CME information and select publications here.

]]>Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management.   

CME information and select publications here.

]]>591ba2c3-a45a-4f07-a715-3e369920d103Tue, 16 Sep 2025 15:00:00 -040054:23falsefull25313125Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event ManagementOcular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event ManagementProf Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer therapies. 

CME information and select publications here.

]]>Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer therapies. 

CME information and select publications here.

]]>169742fc-f18b-4968-b4a5-2e041708289cMon, 15 Sep 2025 15:30:00 -040057:47falsefull25303025Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 1Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 1Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas review available efficacy and safety data guiding the optimal integration of oral SERDs into clinical practice. 

CME information and select publications here.

]]>Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas review available efficacy and safety data guiding the optimal integration of oral SERDs into clinical practice. 

CME information and select publications here.

]]>18b46093-bf67-4ee9-8b6e-c77d88c8f9dfTue, 09 Sep 2025 09:00:00 -040058:36falsefull25292925Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesBreast Cancer — 5-Minute Journal Club Issue 2 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesDr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses the monitoring, mitigation and management of adverse events with available antibody-drug conjugates and novel strategies incorporating ADCs into the breast cancer treatment paradigm.  

CME information and select publications here.

]]>Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses the monitoring, mitigation and management of adverse events with available antibody-drug conjugates and novel strategies incorporating ADCs into the breast cancer treatment paradigm.  

CME information and select publications here.

]]>32dc6bf0-ffee-4b3b-8e54-17360749fcb5Mon, 01 Sep 2025 10:00:00 -040015:43falsefull25282825Brain Metastases with HER2-Positive Breast Cancer — An Interview with Dr Sarah Sammons on Optimal Management ApproachesBrain Metastases with HER2-Positive Breast Cancer — An Interview with Dr Sarah Sammons on Optimal Management ApproachesDr Sarah Sammons from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses cases and reviews the current management of brain metastases in patients with HER2-positive breast cancer. 

CME information and select publications here.

]]>Dr Sarah Sammons from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses cases and reviews the current management of brain metastases in patients with HER2-positive breast cancer. 

CME information and select publications here.

]]>ca4912d8-cda8-4e27-8e98-d6f581c19fc5Tue, 26 Aug 2025 11:30:00 -040045:42falsefull25272725Breast Cancer — 5-Minute Journal Club Issue 1 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesBreast Cancer — 5-Minute Journal Club Issue 1 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug ConjugatesDr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data and shares clinical investigator perspectives on the role of TROP2-directed antibody-drug conjugates in the management of HR-positive and triple-negative breast cancers. 

CME information and select publications here.

]]>Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data and shares clinical investigator perspectives on the role of TROP2-directed antibody-drug conjugates in the management of HR-positive and triple-negative breast cancers. 

CME information and select publications here.

]]>310c8dba-0fae-4056-94ea-ac8492688815Mon, 04 Aug 2025 09:00:00 -040020:18falsefull25262625Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal ManagementEndocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal ManagementDr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, discusses the efficacy and safety of approved and investigational antibody-drug conjugates for endocrine-resistant HR-positive and triple-negative metastatic breast cancer. 

CME information and select publications here.

]]>Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, discusses the efficacy and safety of approved and investigational antibody-drug conjugates for endocrine-resistant HR-positive and triple-negative metastatic breast cancer. 

CME information and select publications here.

]]>ec848e19-b67b-43a2-9d48-22374d22afdaTue, 29 Jul 2025 14:00:00 -040027:45falsefull25252525Metastatic Breast Cancer — Proceedings from a Session Held During the 2025 ASCO Annual MeetingMetastatic Breast Cancer — Proceedings from a Session Held During the 2025 ASCO Annual MeetingDr Harold Burstein, Dr Javier Cortés, Prof Rebecca A Dent, Dr Kevin Kalinsky, Dr Joyce O’Shaughnessy and moderator Dr Hope S Rugo present data informing treatment decision-making for patients with metastatic breast cancer at the 2025 ASCO annual meeting. 

CME information and select publications here.

]]>Dr Harold Burstein, Dr Javier Cortés, Prof Rebecca A Dent, Dr Kevin Kalinsky, Dr Joyce O’Shaughnessy and moderator Dr Hope S Rugo present data informing treatment decision-making for patients with metastatic breast cancer at the 2025 ASCO annual meeting. 

CME information and select publications here.

]]>2ec95d81-41b4-45ca-af93-8de9b2013e8fFri, 04 Jul 2025 09:00:00 -040001:57:47falsefull25242425IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management StrategiesIDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management StrategiesDr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas.  

CME information and select publications here.

]]>Dr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas.  

CME information and select publications here.

]]>d4d6ace0-c41b-433d-913d-4742c96f7e34Mon, 23 Jun 2025 16:00:00 -040054:07falsefull25232325For Oncology Nurses: Hormone Receptor-Positive Breast Cancer — Proceedings from the 2025 Annual ONS CongressFor Oncology Nurses: Hormone Receptor-Positive Breast Cancer — Proceedings from the 2025 Annual ONS CongressDrs Virginia F Borges and Seth Wander summarize the treatment landscape for patients with hormone receptor-positive breast cancer, supported with clinical perspectives and management strategies from nurse practitioners Ms Jamie Carroll and Mr Ronald Stein. 

NCPD information and select publications here.

]]>Drs Virginia F Borges and Seth Wander summarize the treatment landscape for patients with hormone receptor-positive breast cancer, supported with clinical perspectives and management strategies from nurse practitioners Ms Jamie Carroll and Mr Ronald Stein. 

NCPD information and select publications here.

]]>fafa83d6-0788-4f2b-92fa-7fa4e2575a8dMon, 16 Jun 2025 15:38:00 -040001:54:49falsefull25222225Breast Cancer: Additional Perspectives — Year in Review Series on Relevant New Datasets and AdvancesBreast Cancer: Additional Perspectives — Year in Review Series on Relevant New Datasets and AdvancesDr Ian Krop from Yale Cancer Center in New Haven, Connecticut, and Dr Sara Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with breast cancer. 

CME information and select publications here.

]]>Dr Ian Krop from Yale Cancer Center in New Haven, Connecticut, and Dr Sara Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with breast cancer. 

CME information and select publications here.

]]>476d9eb5-37d1-4a1f-9d86-40aa33a7d18fWed, 04 Jun 2025 15:00:00 -040001:01:12falsefull252121255-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer5-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast CancerDr Rinath Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here.

]]>Dr Rinath Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here.

]]>ebce6239-591c-4efa-b5e8-f529bd8d5c87Wed, 28 May 2025 16:00:00 -040013:48falsefull252020255-Minute Journal Club Issue 7 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer5-Minute Journal Club Issue 7 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast CancerDr Rinath M Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here.

]]>Dr Rinath M Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here.

]]>fb023480-bde7-489d-ad62-52166cd367fdMon, 19 May 2025 13:00:00 -040017:35falsefull25191925Breast Cancer — Year in Review Series on Relevant New Datasets and AdvancesBreast Cancer — Year in Review Series on Relevant New Datasets and AdvancesDr Rebecca Dent from National Cancer Centre Singapore and Dr Nancy Lin from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss important efficacy and safety data from 2024 related to the management of localized and advanced breast cancers. 

CME information and select publications here.

]]>Dr Rebecca Dent from National Cancer Centre Singapore and Dr Nancy Lin from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss important efficacy and safety data from 2024 related to the management of localized and advanced breast cancers. 

CME information and select publications here.

]]>a53ac7e7-02b4-4e5e-b1ca-9ecf601e4621Tue, 06 May 2025 15:00:00 -040059:31falsefull25181825For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS CongressFor Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS CongressDr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. 

NCPD information and select publications here.

]]>Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. 

NCPD information and select publications here.

]]>3c8e6575-8c65-4339-93e5-6abfb788c49fSat, 26 Apr 2025 09:00:00 -040001:33:02falsefull25171725Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line TherapyHormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line TherapyDr Adam M Brufsky from the University of Pittsburgh discusses first-line treatment selection for patients with HR-positive metastatic breast cancer and preexisting medical conditions. 

CME information and select publications here.

]]>Dr Adam M Brufsky from the University of Pittsburgh discusses first-line treatment selection for patients with HR-positive metastatic breast cancer and preexisting medical conditions. 

CME information and select publications here.

]]>5e2a910d-1949-4fa4-9c56-e0c740a95b0eFri, 25 Apr 2025 08:30:00 -040052:52falsefull25161625HER2-Positive and Triple-Negative Breast Cancer — Fourth Annual National General Medical Oncology SummitHER2-Positive and Triple-Negative Breast Cancer — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of HER2-positive, triple-negative and localized breast cancer.  

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of HER2-positive, triple-negative and localized breast cancer.  

CME information and select publications here.

]]>5293a48e-39df-48e5-aa49-880682735ab8Mon, 21 Apr 2025 15:00:00 -040001:39:35falsefull25151525HR-Positive Breast Cancer — Fourth Annual National General Medical Oncology SummitHR-Positive Breast Cancer — Fourth Annual National General Medical Oncology SummitClinical investigators discuss available data guiding the management of hormone receptor-positive metastatic breast cancer. 

CME information and select publications here.

]]>Clinical investigators discuss available data guiding the management of hormone receptor-positive metastatic breast cancer. 

CME information and select publications here.

]]>ca28d52d-947d-4108-a221-a3d05ab3523aSun, 13 Apr 2025 09:00:00 -040001:59:29falsefull25141425Breast Cancer — An Interview with Dr Adrienne G Waks on Recent Trial UpdatesBreast Cancer — An Interview with Dr Adrienne G Waks on Recent Trial UpdatesDr Adrienne G Waks from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews recent trial updates and their significance for the management of breast cancer. 

CME information and select publications here.

]]>Dr Adrienne G Waks from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews recent trial updates and their significance for the management of breast cancer. 

CME information and select publications here.

]]>1a465b27-703d-4a2d-9e1d-0df4ee924ba3Tue, 08 Apr 2025 15:00:00 -040054:56falsefull25131325Neurofibromatosis Type 1 Plexiform Neurofibromas — An interview with Dr Christopher L MoertelNeurofibromatosis Type 1 Plexiform Neurofibromas — An interview with Dr Christopher L MoertelDr Christopher L Moertel from the University of Minnesota in Minneapolis discusses the clinical presentation of and optimal management strategies for plexiform neurofibromas and malignancies associated with neurofibromatosis type 1. 

CME information and select publications here.

]]>Dr Christopher L Moertel from the University of Minnesota in Minneapolis discusses the clinical presentation of and optimal management strategies for plexiform neurofibromas and malignancies associated with neurofibromatosis type 1. 

CME information and select publications here.

]]>716751e0-126d-4f06-93d2-4e6b580ae2a0Fri, 28 Mar 2025 16:57:00 -040049:28falsefull25121225HR-Positive Breast Cancer — An Interview with Dr Sara A Hurvitz on the Role of Endocrine-Based TherapyHR-Positive Breast Cancer — An Interview with Dr Sara A Hurvitz on the Role of Endocrine-Based TherapyDr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes data presented at the recent 2024 San Antonio Breast Cancer Symposium applicable to the management of HR-positive breast cancer.   

CME information and select publications here.

]]>Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes data presented at the recent 2024 San Antonio Breast Cancer Symposium applicable to the management of HR-positive breast cancer.   

CME information and select publications here.

]]>12b4d5a8-ab30-42a5-add0-f43cda6f4a82Fri, 28 Mar 2025 08:00:00 -040001:03:10falsefull251111255-Minute Journal Club Issue 6 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer5-Minute Journal Club Issue 6 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast CancerDr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here.

]]>Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here.

]]>cf310033-9235-47c2-b3ea-97e79fd2dafdSat, 22 Mar 2025 06:00:00 -040016:10falsefull25101025Localized Breast Cancer — Examining the Current Use of Genetic Testing and Related Clinical ManagementLocalized Breast Cancer — Examining the Current Use of Genetic Testing and Related Clinical ManagementDr Kevin S Hughes from the Medical University of South Carolina in Charleston and Dr Mark Robson from Memorial Sloan Kettering Cancer Center in New York discuss current BRCA1/2 genetic testing practices and the clinical management of localized breast cancer with alterations in these genes.   

CME information and select publications here.

]]>Dr Kevin S Hughes from the Medical University of South Carolina in Charleston and Dr Mark Robson from Memorial Sloan Kettering Cancer Center in New York discuss current BRCA1/2 genetic testing practices and the clinical management of localized breast cancer with alterations in these genes.   

CME information and select publications here.

]]>a985ccaf-2741-45b9-a5fb-4161b4bc8b03Wed, 12 Mar 2025 12:15:00 -040059:43falsefull2599255-Minute Journal Club Issue 5 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer5-Minute Journal Club Issue 5 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast CancerDr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here.

]]>Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here.

]]>11d09501-1722-4637-a9d9-0b906653f5deTue, 04 Mar 2025 08:00:00 -040018:31falsefull258825HER2-Low and HER2-Ultralow Breast Cancer — A Roundtable Discussion on Current and Future Management StrategiesHER2-Low and HER2-Ultralow Breast Cancer — A Roundtable Discussion on Current and Future Management StrategiesDr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, Dr Mark D Pegram from Stanford Cancer Institute in California, and Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, summarize currently available data guiding treatment decision-making for patients with low and ultralow HER2 expression and present cases from their practices. 

CME information and select publications here.

]]>Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, Dr Mark D Pegram from Stanford Cancer Institute in California, and Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, summarize currently available data guiding treatment decision-making for patients with low and ultralow HER2 expression and present cases from their practices. 

CME information and select publications here.

]]>2003fe0d-6b66-4c02-8b7a-4be51248f23aSat, 15 Feb 2025 10:00:00 -040002:02:17falsefull2577255-Minute Journal Club Issue 4 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer5-Minute Journal Club Issue 4 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast CancerDr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here

]]>Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here

]]>eb482730-d768-489b-9f10-1efaac2a1367Mon, 10 Feb 2025 09:00:00 -040010:06falsefull2566255-Minute Journal Club Issue 3 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer5-Minute Journal Club Issue 3 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast CancerDr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here

]]>Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer. 

CME information and select publications here

]]>8c89841e-77b8-4346-af56-2a7678d06062Fri, 31 Jan 2025 15:00:00 -040011:58falsefull255525Metastatic Triple-Negative Breast Cancer — Oncology Q&A for Clinicians: Discussing Common Questions Posed by PatientsMetastatic Triple-Negative Breast Cancer — Oncology Q&A for Clinicians: Discussing Common Questions Posed by PatientsDr Lisa A Carey from UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from the University of Chicago in Illinois address commonly asked questions from patients diagnosed with metastatic triple-negative breast cancer.   

CME information and select publications here

]]>Dr Lisa A Carey from UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from the University of Chicago in Illinois address commonly asked questions from patients diagnosed with metastatic triple-negative breast cancer.   

CME information and select publications here

]]>af3e510c-0074-4dad-abd9-0db14fb71957Fri, 24 Jan 2025 08:00:00 -040001:00:17falsefull254425Oncology Q&A for Patients with Metastatic Triple-Negative Breast CancerOncology Q&A for Patients with Metastatic Triple-Negative Breast CancerFor this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill and Dr Rita Nanda from The University of Chicago to discuss the patient experience associated with the diagnosis and treatment of metastatic triple-negative breast cancer.

]]>For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill and Dr Rita Nanda from The University of Chicago to discuss the patient experience associated with the diagnosis and treatment of metastatic triple-negative breast cancer.

]]>4F9F9288-6AF0-44E1-822D-B2DEAAD16BB2Fri, 17 Jan 2025 15:55:00 -040001:00:59falsefull253325For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill and Dr Rita Nanda from The University of Chicago to discuss the patient experience associated with the diagnosis and treatment of metastatic triple-negative breast cancer.Metastatic Breast Cancer — San Antonio 2024 symposium series proceedings Part 3Metastatic Breast Cancer — San Antonio 2024 symposium series proceedings Part 3Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville, Tennessee, Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, Dr Joyce O’Shaughnessy from the Sarah Cannon Research Institute in Dallas, Texas, and Dr Sara M Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss available and novel treatment strategies for metastatic breast cancer.

]]>Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville, Tennessee, Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, Dr Joyce O’Shaughnessy from the Sarah Cannon Research Institute in Dallas, Texas, and Dr Sara M Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss available and novel treatment strategies for metastatic breast cancer.

]]>A8457C90-D660-4944-B0F7-35BAB6F796B1Fri, 10 Jan 2025 14:09:00 -040002:01:00falsefull252225Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville, Tennessee, Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, Dr Joyce O’Shaughnessy from the Sarah Cannon Research Institute in Dallas, Texas, and Dr Sara M Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss available and novel treatment strategies for metastatic breast cancer.The Role of Endocrine-Based Therapy in the Management of Breast Cancer — San Antonio 2024 symposium series proceedings Part 2The Role of Endocrine-Based Therapy in the Management of Breast Cancer — San Antonio 2024 symposium series proceedings Part 2Dr Matthew Goetz from Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, Dr Sara Hurvitz from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, and Dr Seth Wander from Massachusetts General Hospital in Boston share their perspectives on the management of hormone receptor-positive breast cancers and the potential role of emerging data from SABCS 2024.

]]>Dr Matthew Goetz from Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, Dr Sara Hurvitz from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, and Dr Seth Wander from Massachusetts General Hospital in Boston share their perspectives on the management of hormone receptor-positive breast cancers and the potential role of emerging data from SABCS 2024.

]]>E114EF85-E010-48F7-8DB9-B9BCEAD3785FFri, 03 Jan 2025 10:34:00 -040002:00:37falsefull251125Dr Matthew Goetz from Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota, Dr Sara Hurvitz from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, and Dr Seth Wander from Massachusetts General Hospital in Boston share their perspectives on the management of hormone receptor-positive breast cancers and the potential role of emerging data from SABCS 2024.HER2-Low and HER2-Ultralow Breast Cancer — San Antonio 2024 symposium series proceedings Part 1HER2-Low and HER2-Ultralow Breast Cancer — San Antonio 2024 symposium series proceedings Part 1Dr Aditya Bardia, Professor Giuseppe Curigliano, Dr Hope Rugo and Dr Antonio C Wolff share their perspectives on the management of HER2-low breast cancer and the potential role of emerging data from SABCS 2024.

]]>Dr Aditya Bardia, Professor Giuseppe Curigliano, Dr Hope Rugo and Dr Antonio C Wolff share their perspectives on the management of HER2-low breast cancer and the potential role of emerging data from SABCS 2024.

]]>1905D777-91BE-4A10-BEFB-C6F25B296555Mon, 23 Dec 2024 11:54:00 -040001:31:29falsefull24242424Dr Aditya Bardia, Professor Giuseppe Curigliano, Dr Hope Rugo and Dr Antonio C Wolff share their perspectives on the management of HER2-low breast cancer and the potential role of emerging data from SABCS 2024.5-Minute Journal Club Issue 2 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer5-Minute Journal Club Issue 2 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast CancerDr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.

]]>Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.

]]>13258011-B5C4-4A34-84EA-ED8A8C85A94CMon, 16 Dec 2024 12:16:00 -040011:59falsefull24232324Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast CancerExploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast CancerDr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss recent updates on available and novel treatment strategies for metastatic triple-negative breast cancer.

]]>Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss recent updates on available and novel treatment strategies for metastatic triple-negative breast cancer.

]]>F888774E-B74D-43D7-ACE0-47730B7B7E1CThu, 05 Dec 2024 11:45:00 -040059:42falsefull24222224Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss recent updates on available and novel treatment strategies for metastatic triple-negative breast cancer.5-Minute Journal Club Issue 1 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer5-Minute Journal Club Issue 1 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast CancerDr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral selective estrogen receptor degraders for ER-positive metastatic breast cancer.

]]>Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral selective estrogen receptor degraders for ER-positive metastatic breast cancer.

]]>AFA16201-E953-442B-8AA5-323528409131Tue, 26 Nov 2024 12:49:00 -040010:56falsefull24212124Dr Seth Wander from Massachusetts General Hospital in Boston discusses recent developments with oral selective estrogen receptor degraders for ER-positive metastatic breast cancer.Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway AbnormalitiesOptimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway AbnormalitiesDr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations.

]]>Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations.

]]>85398A8A-6DEF-4121-A9EA-E738F0F59633Tue, 19 Nov 2024 09:51:00 -040056:49falsefull24202024Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Hope S Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center discuss treatment decision-making for HR-positive metastatic breast cancer in patients who harbor PI3K/AKT/PTEN pathway mutations.Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Breast CancerData + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Breast CancerSpecialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with HR-positive breast cancer.

]]>Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with HR-positive breast cancer.

]]>F449BB2E-8DFF-4B76-8AAF-95AC5E473D26Fri, 15 Nov 2024 21:33:00 -040001:03:53falsefull24191924Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with HR-positive breast cancer.Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast CancerImproving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast CancerProf Francois-Clement Bidard from Institut Curie in Paris and Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta discuss improving the outcomes of first-line endocrine-based therapy for patients with HR-positive, HER2-negative metastatic breast cancer.

]]>Prof Francois-Clement Bidard from Institut Curie in Paris and Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta discuss improving the outcomes of first-line endocrine-based therapy for patients with HR-positive, HER2-negative metastatic breast cancer.

]]>4B433D0F-2431-4F5F-B6D1-60516DCE4023Fri, 01 Nov 2024 11:45:00 -040059:29falsefull24181824Prof Francois-Clement Bidard from Institut Curie in Paris and Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta discuss improving the outcomes of first-line endocrine-based therapy for patients with HR-positive, HER2-negative metastatic breast cancer.Oncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast CancerOncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast CancerDr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer.

]]>Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer.

]]>761B10BE-2362-49E5-908D-2AB2E58A2A04Fri, 25 Oct 2024 11:26:00 -040045:46falsefull24171724Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer.Practical Perspectives: Optimizing Diagnosis and Treatment for Patients with Desmoid TumorsPractical Perspectives: Optimizing Diagnosis and Treatment for Patients with Desmoid TumorsDr Thierry Alcindor from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for desmoid tumors and review novel options for targeted therapy.

]]>Dr Thierry Alcindor from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for desmoid tumors and review novel options for targeted therapy.

]]>BB3AFFBD-9868-4C66-B7FE-5165163F0C51Fri, 18 Oct 2024 12:41:00 -040059:22falsefull24161624Dr Thierry Alcindor from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Mrinal Gounder from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for desmoid tumors and review novel options for targeted therapy.Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast CancerOncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast CancerDr Tiffany Traina from the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York, New York, discusses optimizing the management of metastatic BRCA-negative, triple-negative breast cancer.

]]>Dr Tiffany Traina from the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York, New York, discusses optimizing the management of metastatic BRCA-negative, triple-negative breast cancer.

]]>C38A0B92-D0CB-4155-82D1-F87A73ECE55CWed, 25 Sep 2024 12:14:00 -040049:55falsefull24151524Dr Tiffany Traina from the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York, New York, discusses optimizing the management of metastatic BRCA-negative, triple-negative breast cancer.Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast CancerInside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast CancerProf Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.

]]>Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.

]]>BBD7AC91-E56F-49D2-83BE-F2ABC5AE0D65Fri, 06 Sep 2024 13:52:00 -040001:02:34falsefull24141424Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Breast Cancer from the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingOncology Today with Dr Neil Love: Special Edition — Key Presentations on Breast Cancer from the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingDr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting.

]]>Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting.

]]>D99467A2-61E6-432F-A7E8-2F94054BA6A4Thu, 29 Aug 2024 11:22:00 -040001:15:59falsefull24131324Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, discusses recent advances in the treatment of breast cancer following the 2024 ASCO Annual Meeting.Oncology Today with Dr Neil Love: An interview with Professor Giuseppe Curigliano, MD, PhD — Management of Metastatic Breast CancerOncology Today with Dr Neil Love: An interview with Professor Giuseppe Curigliano, MD, PhD — Management of Metastatic Breast CancerProf Giuseppe Curigliano from the European Institute of Oncology in Milano, Italy discusses current questions and controversies in the management of metastatic breast cancer.

]]>Prof Giuseppe Curigliano from the European Institute of Oncology in Milano, Italy discusses current questions and controversies in the management of metastatic breast cancer.

]]>BA5618A7-8D53-4680-97EC-5612220FC801Fri, 23 Aug 2024 12:37:00 -040046:13falsefull24121224Prof Giuseppe Curigliano from the European Institute of Oncology in Milano, Italy discusses current questions and controversies in the management of metastatic breast cancer.Oncology Today with Dr Neil Love: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast CancerOncology Today with Dr Neil Love: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast CancerDr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes recent trials investigating the integration of antibody-drug conjugates for HR-positive and triple-negative metastatic breast cancer.

]]>Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes recent trials investigating the integration of antibody-drug conjugates for HR-positive and triple-negative metastatic breast cancer.

]]>BC8024FE-A253-437E-8BF0-0991963494A7Fri, 16 Aug 2024 15:10:00 -040054:18falsefull24111124Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes recent trials investigating the integration of antibody-drug conjugates for HR-positive and triple-negative metastatic breast cancer.Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast CancerIndividualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast CancerDr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with HR-positive metastatic breast cancer.

]]>Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with HR-positive metastatic breast cancer.

]]>7CBCF5A9-C622-42E6-9F2A-1E9FB3BCC93FWed, 07 Aug 2024 10:20:00 -040001:15:00falsefull24101024Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, summarizes risk factors and targeted therapy options for patients with HR-positive metastatic breast cancer.Oncology Today with Dr Neil Love: Optimizing the Identification of HER2-Low Breast CancerOncology Today with Dr Neil Love: Optimizing the Identification of HER2-Low Breast CancerDr Kimberly H Allison from Stanford Cancer Institute in Stanford, California, discusses the optimal identification, pathologic reporting and treatment of HER2-low breast cancer.

]]>Dr Kimberly H Allison from Stanford Cancer Institute in Stanford, California, discusses the optimal identification, pathologic reporting and treatment of HER2-low breast cancer.

]]>E0B2154C-C6D6-42D0-AB7D-3BEB1E39559DWed, 31 Jul 2024 11:06:00 -040023:49falsefull249924Dr Kimberly H Allison from Stanford Cancer Institute in Stanford, California, discusses the optimal identification, pathologic reporting and treatment of HER2-low breast cancer.What Clinicians Want to Know About the Management of Triple-Negative Breast CancerWhat Clinicians Want to Know About the Management of Triple-Negative Breast CancerDr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Heather McArthur from UT Southwestern Medical Center in Dallas, Texas, summarize the evolution of biomarker-driven treatment approaches for triple-negative breast cancer.

]]>Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Heather McArthur from UT Southwestern Medical Center in Dallas, Texas, summarize the evolution of biomarker-driven treatment approaches for triple-negative breast cancer.

]]>D6010456-634D-48F4-962A-268297E9BA60Thu, 11 Jul 2024 09:56:00 -040001:03:58falsefull248824Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Heather McArthur from UT Southwestern Medical Center in Dallas, Texas, summarize the evolution of biomarker-driven treatment approaches for triple-negative breast cancer.Striving for Consensus: Exploring the Current Role of Ovarian Suppression in the Management of Breast CancerStriving for Consensus: Exploring the Current Role of Ovarian Suppression in the Management of Breast CancerDr William J Gradishar from Northwestern Medicine Feinberg School of Medicine in Chicago, Illinois, Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Seth Wander from Massachusetts General Hospital in Boston, discuss key findings and practical considerations with ovarian function suppression for hormone receptor-positive breast cancer.

]]>Dr William J Gradishar from Northwestern Medicine Feinberg School of Medicine in Chicago, Illinois, Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Seth Wander from Massachusetts General Hospital in Boston, discuss key findings and practical considerations with ovarian function suppression for hormone receptor-positive breast cancer.

]]>BB2C0914-304E-4ACD-A968-0EEE1F28C89AThu, 13 Jun 2024 10:03:00 -040002:35:49falsefull247724Dr William J Gradishar from Northwestern Medicine Feinberg School of Medicine in Chicago, Illinois, Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Seth Wander from Massachusetts General Hospital in Boston, discuss key findings and practical considerations with ovarian function suppression for hormone receptor-positive breast cancer.Oncology Today with Dr Neil Love: Understanding the Risk of Recurrence and Related Management for Patients with Localized HER2-Positive Breast CancerOncology Today with Dr Neil Love: Understanding the Risk of Recurrence and Related Management for Patients with Localized HER2-Positive Breast CancerDr Adam M Brufsky from UPMC Hillman Cancer Center in Pittsburgh summarizes the history of and modern advances in treating localized HER2-positive breast cancers, including strategies for monitoring and managing treatment-related toxicities.

]]>Dr Adam M Brufsky from UPMC Hillman Cancer Center in Pittsburgh summarizes the history of and modern advances in treating localized HER2-positive breast cancers, including strategies for monitoring and managing treatment-related toxicities.

]]>F3408E99-AD45-40B9-8C21-3FE1C74D9E09Tue, 21 May 2024 12:12:00 -040001:16:31falsefull246624Dr Adam M Brufsky from UPMC Hillman Cancer Center in Pittsburgh summarizes the history of and modern advances in treating localized HER2-positive breast cancers, including strategies for monitoring and managing treatment-related toxicities.Virtual Case Library: Metastatic Triple-Negative Breast CancerVirtual Case Library: Metastatic Triple-Negative Breast CancerDrs Rita Nanda, Sara M Tolaney, Julia Foldi, Laura Huppert and Saba Shaikh discuss available and emerging research, patient cases from participating junior clinical investigators and senior clinical investigator perspectives on relevant research data informing clinical decision-making for patients with metastatic triple-negative breast cancer.

]]>Drs Rita Nanda, Sara M Tolaney, Julia Foldi, Laura Huppert and Saba Shaikh discuss available and emerging research, patient cases from participating junior clinical investigators and senior clinical investigator perspectives on relevant research data informing clinical decision-making for patients with metastatic triple-negative breast cancer.

]]>4C57F502-196A-4780-B8AA-66FB3EE0036AThu, 09 May 2024 10:46:00 -040002:13:01falsefull245524Drs Rita Nanda, Sara M Tolaney, Julia Foldi, Laura Huppert and Saba Shaikh discuss available and emerging research, patient cases from participating junior clinical investigators and senior clinical investigator perspectives on relevant research data informing clinical decision-making for patients with metastatic triple-negative breast cancer.Oncology Today with Dr Neil Love: Overcoming Endocrine Resistance in ER-Positive Metastatic Breast CancerOncology Today with Dr Neil Love: Overcoming Endocrine Resistance in ER-Positive Metastatic Breast CancerDr Seth Wander from Harvard Medical School in Boston, Massachusetts, discusses mechanisms underlying endocrine resistance in breast cancer and optimal therapeutic approaches for patients who experience disease progression while or after receiving endocrine therapy.

]]>Dr Seth Wander from Harvard Medical School in Boston, Massachusetts, discusses mechanisms underlying endocrine resistance in breast cancer and optimal therapeutic approaches for patients who experience disease progression while or after receiving endocrine therapy.

]]>42170C8F-9EE3-49EE-8C1B-D90319F258C1Tue, 26 Mar 2024 08:59:00 -040001:19:56falsefull244424Dr Seth Wander from Harvard Medical School in Boston, Massachusetts, discusses mechanisms underlying endocrine resistance in breast cancer and optimal therapeutic approaches for patients who experience disease progression while or after receiving endocrine therapy.Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast CancerYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast CancerDr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss patient cases and treatment strategies for HER2-positive and triple-negative breast cancer.

]]>Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss patient cases and treatment strategies for HER2-positive and triple-negative breast cancer.

]]>64B551FE-8B72-40EE-B1DB-5444FA2180CBFri, 15 Mar 2024 09:07:00 -040001:05:47falsefull243324Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss patient cases and treatment strategies for HER2-positive and triple-negative breast cancer.Oncology Today with Dr Neil Love: Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast CancerOncology Today with Dr Neil Love: Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast CancerDr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York City discusses available and emerging data with oral SERDs for patients with ER-positive metastatic breast cancer.

]]>Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York City discusses available and emerging data with oral SERDs for patients with ER-positive metastatic breast cancer.

]]>005C1DE6-0C8D-49E5-9C0D-D6DC51F938D1Mon, 11 Mar 2024 08:04:00 -040037:38falsefull242224Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York City discusses available and emerging data with oral SERDs for patients with ER-positive metastatic breast cancer.Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast CancerYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast CancerDr Stephanie L Graff from the Legorreta Cancer Center at Brown University in Providence, Rhode Island, and Dr Erica Mayer from Dana-Farber Cancer Institute in Boston discuss treatment decision-making involving approved and investigational strategies for the management of hormone receptor-positive breast cancer.

]]>Dr Stephanie L Graff from the Legorreta Cancer Center at Brown University in Providence, Rhode Island, and Dr Erica Mayer from Dana-Farber Cancer Institute in Boston discuss treatment decision-making involving approved and investigational strategies for the management of hormone receptor-positive breast cancer.

]]>51962E3D-B56B-4284-9508-A533B4FC5DA9Thu, 01 Feb 2024 10:15:00 -040001:04:53falsefull241124Dr Stephanie L Graff from the Legorreta Cancer Center at Brown University in Providence, Rhode Island, and Dr Erica Mayer from Dana-Farber Cancer Institute in Boston discuss treatment decision-making involving approved and investigational strategies for the management of hormone receptor-positive breast cancer.Implications of Recent Data Sets for the Current and Future Management of Breast CancerImplications of Recent Data Sets for the Current and Future Management of Breast CancerDr Aditya Bardia from Massachusetts General Hospital and Dr Sara M Tolaney from the Dana-Farber Cancer Institute, both in Boston, Massachusetts, discuss key presentations on the management of breast cancer from the 2023 ESMO Congress.

]]>Dr Aditya Bardia from Massachusetts General Hospital and Dr Sara M Tolaney from the Dana-Farber Cancer Institute, both in Boston, Massachusetts, discuss key presentations on the management of breast cancer from the 2023 ESMO Congress.

]]>0E603242-7E99-4208-A908-395C06DE0D66Thu, 30 Nov 2023 08:37:00 -040001:03:09falsefull23151523Dr Aditya Bardia from Massachusetts General Hospital and Dr Sara M Tolaney from the Dana-Farber Cancer Institute, both in Boston, Massachusetts, discuss key presentations on the management of breast cancer from the 2023 ESMO Congress.Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast CancerInside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast CancerDr Hope Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Tiffany Traina from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging optimal management approaches for metastatic triple-negative breast cancer.

]]>Dr Hope Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Tiffany Traina from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging optimal management approaches for metastatic triple-negative breast cancer.

]]>E84133D9-F06F-4DE7-8AEA-152769F6B36FFri, 29 Sep 2023 14:38:00 -040001:04:49falsefull23141423Dr Hope Rugo from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Tiffany Traina from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging optimal management approaches for metastatic triple-negative breast cancer.Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 2 of a 2-Part SeriesMeet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 2 of a 2-Part SeriesDr Richard F Riedel from Duke Cancer Institute in Durham, North Carolina, discusses approved and novel treatment approaches for soft tissue sarcoma, moderated by Dr Neil Love.

]]>Dr Richard F Riedel from Duke Cancer Institute in Durham, North Carolina, discusses approved and novel treatment approaches for soft tissue sarcoma, moderated by Dr Neil Love.

]]>12D7CE8F-5B59-414F-9F19-A0FF45B01A0EWed, 30 Aug 2023 11:13:00 -040001:01:53falsefull23131323Dr Richard F Riedel from Duke Cancer Institute in Durham, North Carolina, discusses approved and novel treatment approaches for soft tissue sarcoma, moderated by Dr Neil Love.Inside the Issue: Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 InhibitorInside the Issue: Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 InhibitorDr Aditya Bardia from Massachusetts General Hospital in Boston, Massachusetts, and Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discuss approved and novel treatment approaches for ER-positive metastatic breast cancer that has progressed on prior CDK4/6 inhibitor therapy.

]]>Dr Aditya Bardia from Massachusetts General Hospital in Boston, Massachusetts, and Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discuss approved and novel treatment approaches for ER-positive metastatic breast cancer that has progressed on prior CDK4/6 inhibitor therapy.

]]>A9107372-277E-4947-AB2B-01CF2B3DA4A8Thu, 24 Aug 2023 11:57:00 -040001:01:15falsefull23121223Dr Aditya Bardia from Massachusetts General Hospital in Boston, Massachusetts, and Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discuss approved and novel treatment approaches for ER-positive metastatic breast cancer that has progressed on prior CDK4/6 inhibitor therapy.Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Breast Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingOncology Today with Dr Neil Love: Special Edition — Key Presentations on Breast Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingDr Heather McArthur from the UT Southwestern Medical Center in Dallas, Texas discusses key presentations on breast cancer from the 2023 ASCO Annual meeting.

]]>Dr Heather McArthur from the UT Southwestern Medical Center in Dallas, Texas discusses key presentations on breast cancer from the 2023 ASCO Annual meeting.

]]>CF901F25-66C5-4D70-B809-AD2A53775F63Wed, 09 Aug 2023 11:25:00 -040001:25:35falsefull23111123Dr Heather McArthur from the UT Southwestern Medical Center in Dallas, Texas discusses key presentations on breast cancer from the 2023 ASCO Annual meeting.Oncology Today with Dr Neil Love: Special Edition — Current and Future Management of Breast CancerOncology Today with Dr Neil Love: Special Edition — Current and Future Management of Breast CancerFeaturing a discussion on recent presentations in breast cancer from the 2023 ASCO annual meeting with Dr Kevin Kalinsky, moderated by Dr Neil Love.

]]>Featuring a discussion on recent presentations in breast cancer from the 2023 ASCO annual meeting with Dr Kevin Kalinsky, moderated by Dr Neil Love.

]]>2BB58275-D374-4821-AAE6-CC465C30BC40Fri, 21 Jul 2023 13:41:00 -040058:52falsefull23101023Featuring a discussion on recent presentations in breast cancer from the 2023 ASCO annual meeting with Dr Kevin Kalinsky, moderated by Dr Neil Love.Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 1 of a 2-Part SeriesMeet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 1 of a 2-Part SeriesFeaturing a discussion on the management of soft tissue sarcoma and related connective tissue disorders with Dr Brian Van Tine, moderated by Dr Neil Love.

]]>Featuring a discussion on the management of soft tissue sarcoma and related connective tissue disorders with Dr Brian Van Tine, moderated by Dr Neil Love.

]]>A8641C54-929D-4076-AF5F-5C38D0324F09Fri, 16 Jun 2023 10:41:00 -040001:01:32falsefull239923Featuring a discussion on the management of soft tissue sarcoma and related connective tissue disorders with Dr Brian Van Tine, moderated by Dr Neil Love.Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 3 of a 3-Part SeriesMeet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 3 of a 3-Part SeriesFeaturing a discussion on the management of ER-positive and triple-negative breast cancer with Dr Sara A Hurvitz, moderated by Dr Neil Love.

]]>Featuring a discussion on the management of ER-positive and triple-negative breast cancer with Dr Sara A Hurvitz, moderated by Dr Neil Love.

]]>C9EDBD1B-87E4-4DD9-98DD-2A0F3C95B7D5Thu, 27 Apr 2023 10:26:00 -040001:00:29falsefull238823Featuring a discussion on the management of ER-positive and triple-negative breast cancer with Dr Sara A Hurvitz, moderated by Dr Neil Love.Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 2 of a 3-Part SeriesMeet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 2 of a 3-Part SeriesFeaturing a discussion on the management of ER-positive and triple-negative breast cancer with Dr Sara Tolaney, moderated by Dr Neil Love. ?

]]>Featuring a discussion on the management of ER-positive and triple-negative breast cancer with Dr Sara Tolaney, moderated by Dr Neil Love. ?

]]>31F6D202-E35B-4CA5-A396-6AECDD630247Fri, 31 Mar 2023 11:56:00 -040001:00:31falsefull237723Featuring a discussion on the management of ER-positive and triple-negative breast cancer with Dr Sara Tolaney, moderated by Dr Neil Love.Recent Advances and Future Directions in Breast Cancer — With Dr Harold Burstein and Dr Virginia Kaklamani (Proceedings from a Symposium in Partnership with NCOA and SCOS)Recent Advances and Future Directions in Breast Cancer — With Dr Harold Burstein and Dr Virginia Kaklamani (Proceedings from a Symposium in Partnership with NCOA and SCOS)Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

]]>Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

]]>CD63276E-9F99-4CBA-AD8F-40A5C16C4C00Fri, 17 Mar 2023 12:14:00 -040059:04falsefull236623Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.Inside the Issue — Exploring the Current Role of Ovarian Suppression in the Management of Breast CancerInside the Issue — Exploring the Current Role of Ovarian Suppression in the Management of Breast CancerFeaturing a discussion on the current role of ovarian suppression in the management of breast cancer with Drs Kathy Miller and Ann Partridge, moderated by Dr Neil Love.

]]>Featuring a discussion on the current role of ovarian suppression in the management of breast cancer with Drs Kathy Miller and Ann Partridge, moderated by Dr Neil Love.

]]>FD8015B4-FDB0-4598-9B52-1AE5E3FB21CDFri, 10 Mar 2023 08:54:00 -040001:02:32falsefull235523Featuring a discussion on the current role of ovarian suppression in the management of breast cancer with Drs Kathy Miller and Ann Partridge, moderated by Dr Neil Love.Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 1 of a 3-Part SeriesMeet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 1 of a 3-Part SeriesFeaturing a discussion on the management of ER-positive and triple-negative breast cancer with Dr Komal Jhaveri, moderated by Dr Neil Love.

]]>Featuring a discussion on the management of ER-positive and triple-negative breast cancer with Dr Komal Jhaveri, moderated by Dr Neil Love.

]]>7D249F4C-66F1-4C6C-906A-881873EBD61FFri, 24 Feb 2023 10:27:00 -040001:03:18falsefull234423Featuring a discussion on the management of ER-positive and triple-negative breast cancer with Dr Komal Jhaveri, moderated by Dr Neil Love.Oncology Today with Dr Neil Love: Special Edition — Management of ER-Positive Breast CancerOncology Today with Dr Neil Love: Special Edition — Management of ER-Positive Breast CancerFeaturing a discussion on ER-positive breast cancer with Drs Erica Mayer and Ruth O’Regan, moderated by Dr Neil Love.

]]>Featuring a discussion on ER-positive breast cancer with Drs Erica Mayer and Ruth O’Regan, moderated by Dr Neil Love.

]]>A704D20C-8D92-4732-ACC4-A67ED89AD69BTue, 31 Jan 2023 10:54:00 -040001:40:11falsefull233323Featuring a discussion on ER-positive breast cancer with Drs Erica Mayer and Ruth O’Regan, moderated by Dr Neil Love.Oncology Today with Dr Neil Love: HER2-Positive Metastatic Breast CancerOncology Today with Dr Neil Love: HER2-Positive Metastatic Breast CancerFeaturing a discussion of recent advances in the treatment of HER2-positive metastatic breast cancer with Professor Giuseppe Curigliano, moderated by Dr Neil Love.

]]>Featuring a discussion of recent advances in the treatment of HER2-positive metastatic breast cancer with Professor Giuseppe Curigliano, moderated by Dr Neil Love.

]]>C256D298-1D6E-4A60-B0EF-3BE0974AAB07Thu, 26 Jan 2023 11:06:00 -040047:04falsefull232223Featuring a discussion of recent advances in the treatment of HER2-positive metastatic breast cancer with Professor Giuseppe Curigliano, moderated by Dr Neil Love.Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Breast CancerYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Breast CancerProceedings from our Year in Review webinar on the management of breast cancer. Featuring perspectives from Dr Joyce O’Shaughnessy and Prof Peter Schmid, moderated by Dr Neil Love.

]]>Proceedings from our Year in Review webinar on the management of breast cancer. Featuring perspectives from Dr Joyce O’Shaughnessy and Prof Peter Schmid, moderated by Dr Neil Love.

]]>547F74C9-7718-4AFA-A249-E2A6B4895C92Tue, 17 Jan 2023 11:15:00 -040001:00:53falsefull231123Proceedings from our Year in Review webinar on the management of breast cancer. Featuring perspectives from Dr Joyce O’Shaughnessy and Prof Peter Schmid, moderated by Dr Neil Love.